Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 97 articles:
HTML format
Text format



Single Articles


    January 2016
  1. MULLER C, Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al
    Characterization of high risk melanoma patients in Austria.
    Br J Dermatol. 2016 Jan 22. doi: 10.1111/bjd.14407.
    PubMed     Text format     Abstract available


  2. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.
    Br J Dermatol. 2016 Jan 20. doi: 10.1111/bjd.14279.
    PubMed     Text format    


  3. CHMIELOWSKI B
    Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma.
    Br J Dermatol. 2016;174:20.
    PubMed     Text format    


    December 2015
  4. FERNANDEZ-VEGA I, Santos-Juanes J, Fresno-Forcelledo MF
    Primary amelanotic rhabdoid melanoma of the forehead.
    Br J Dermatol. 2015 Dec 29. doi: 10.1111/bjd.14382.
    PubMed     Text format     Abstract available


  5. ROACH RE, Plasmeijer EI, van Doorn R, Bergman W, et al
    The value of clinical characteristics for the diagnosis of melanoma in patients presenting at a pigmented lesion clinic.
    Br J Dermatol. 2015 Dec 26. doi: 10.1111/bjd.14375.
    PubMed     Text format     Abstract available


  6. EISEMANN N, Jansen L, Castro FA, Chen T, et al
    Survival from non-melanoma skin cancer in Germany.
    Br J Dermatol. 2015 Dec 16. doi: 10.1111/bjd.14352.
    PubMed     Text format     Abstract available


  7. FRAUCHIGER AL, Mangana J, Rechsteiner M, Moch H, et al
    Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status.
    Br J Dermatol. 2015 Dec 13. doi: 10.1111/bjd.14347.
    PubMed     Text format     Abstract available


  8. CURL PK
    Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment.
    Br J Dermatol. 2015;173:1365-6.
    PubMed     Text format    


    November 2015
  9. TSCHANDL P, Berghoff AS, Preusser M, Pammer J, et al
    Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and nevi in vivo.
    Br J Dermatol. 2015 Nov 28. doi: 10.1111/bjd.14323.
    PubMed     Text format     Abstract available


  10. MONCRIEFF M, Fadhil M, Garrioch J
    Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience.
    Br J Dermatol. 2015 Nov 24. doi: 10.1111/bjd.14314.
    PubMed     Text format     Abstract available


  11. GUIDA S, Pellacani G, Cesinaro AM, Moscarella E, et al
    Spitz naevi and melanomas with similar dermoscopic pattern: can confocal microscopy differentiate?
    Br J Dermatol. 2015 Nov 11. doi: 10.1111/bjd.14286.
    PubMed     Text format     Abstract available


  12. SEBARATNAM DF, Anforth R, Fernandez-Penas P
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma.
    Br J Dermatol. 2015 Nov 2. doi: 10.1111/bjd.14264.
    PubMed     Text format     Abstract available


    October 2015
  13. RIBERO S, Zugna D, Osella-Abate S, Glass D, et al
    Prediction of high naevus count in a healthy UK population to estimate melanoma risk.
    Br J Dermatol. 2015 Oct 19. doi: 10.1111/bjd.14216.
    PubMed     Text format     Abstract available


    September 2015
  14. MOSER J, Moshammer R, Koglbauer G, Kitzwogerer M, et al
    Sentinel-node biopsy in melanoma: A single center experience with 216 consecutive patients.
    Br J Dermatol. 2015 Sep 24. doi: 10.1111/bjd.14189.
    PubMed     Text format     Abstract available


  15. ZARAGOZA J, Caille A, Beneton N, Bens G, et al
    Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
    Br J Dermatol. 2015 Sep 6. doi: 10.1111/bjd.14155.
    PubMed     Text format     Abstract available


  16. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.
    Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152.
    PubMed     Text format     Abstract available


  17. KRAFT S, Tsao H
    Melanoma-associated naevi: precursors or coincidence?
    Br J Dermatol. 2015;173:633-4.
    PubMed     Text format    


  18. SCHOFIELD JK
    Sentinel lymph node biopsy: in support of equity of access, informed shared decision making and patient choice.
    Br J Dermatol. 2015;173:863-4.
    PubMed     Text format    


    August 2015
  19. MONCRIEFF M, Garioch J
    MSLT-I: it's all about the lymph nodes....
    Br J Dermatol. 2015;173:626-7.
    PubMed     Text format    


  20. MCGREGOR JM, Sasieni P
    MSLT-I: it's all about the lymph nodes...: reply from the authors.
    Br J Dermatol. 2015;173:627-8.
    PubMed     Text format    


    July 2015
  21. BENATI E, Argenziano G, Kyrgidis A, Moscarella E, et al
    Melanoma and naevi with globular pattern: Confocal microscopy as an aid for diagnostic differentiation.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14049.
    PubMed     Text format     Abstract available


  22. LALLAS A, Kyrgidis A, Koga H, Moscarella E, et al
    The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14045.
    PubMed     Text format     Abstract available


  23. LI Z, Wang Z, Yu Y, Zhang H, et al
    Smoking is Inversely Related to Cutaneous Malignant Melanoma -Says Results from a Meta-analysis.
    Br J Dermatol. 2015 Jul 2. doi: 10.1111/bjd.13998.
    PubMed     Text format     Abstract available


  24. DAVIES MA
    BRAF in early stage melanoma: rationale for testing and treatment?
    Br J Dermatol. 2015;173:9-10.
    PubMed     Text format    


    June 2015
  25. SINHA R, Larkin J, Gore M, Fearfield L, et al
    Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Br J Dermatol. 2015 Jun 24. doi: 10.1111/bjd.13958.
    PubMed     Text format     Abstract available


    May 2015
  26. THOMAS L
    Dermoscopy for melanoma: don't forget to take a photo.
    Br J Dermatol. 2015;172:1182-3.
    PubMed     Text format    


    April 2015
  27. JAFARI SM, Hunger RE, Shafighi M
    Lack of strong evidence in depth of thick melanoma excision.
    Br J Dermatol. 2015 Apr 27. doi: 10.1111/bjd.13871.
    PubMed     Text format     Abstract available


  28. PIZZICHETTA MA, Kittler H, Stanganelli I, Bono R, et al
    Pigmented nodular melanoma: The predictive value of dermoscopic features using a multivariate analysis.
    Br J Dermatol. 2015 Apr 27. doi: 10.1111/bjd.13861.
    PubMed     Text format     Abstract available


  29. SHITARAA D, Tell-Marti G, Badenas C, Enokihara MM, et al
    Mutational status of nevus associated-melanomas.
    Br J Dermatol. 2015 Apr 9. doi: 10.1111/bjd.13829.
    PubMed     Text format     Abstract available


  30. MARCHIORI BAKOS R
    Dermoscopy of naevoid melanoma.
    Br J Dermatol. 2015;172:848-9.
    PubMed     Text format    


  31. IDORN LW
    New insights into the association of socioeconomic status with cutaneous malignant melanoma.
    Br J Dermatol. 2015;172:846-7.
    PubMed     Text format    


  32. OAKLEY AM
    Mobile teledermatology is here to stay.
    Br J Dermatol. 2015;172:856-7.
    PubMed     Text format    


  33. MANAHAN MN, Soyer HP, Loescher LJ, Horsham C, et al
    A pilot trial of mobile, patient-performed teledermoscopy.
    Br J Dermatol. 2015;172:1072-80.
    PubMed     Text format     Abstract available


  34. DEBARBIEUX S, Gaspar R, Depaepe L, Dalle S, et al
    Intraoperative diagnosis of nonpigmented nail tumours with ex vivo fluorescence confocal microscopy: 10 cases.
    Br J Dermatol. 2015;172:1037-44.
    PubMed     Text format     Abstract available


    March 2015
  35. MAR VJ, Liu W, Devitt B, Wong SQ, et al
    The role of BRAF mutations in primary melanoma growth rate and survival.
    Br J Dermatol. 2015 Mar 5. doi: 10.1111/bjd.13756.
    PubMed     Text format     Abstract available


  36. FARIES MB, Cochran AJ, Elashoff RM, Thompson JF, et al
    Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: Response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal
    Br J Dermatol. 2015;172:571-3.
    PubMed     Text format     Abstract available


  37. SLADDEN M, Zagarella S, Popescu C, Bigby M, et al
    No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.
    Br J Dermatol. 2015;172:566-71.
    PubMed     Text format     Abstract available


  38. ATTARD NR
    Head and neck melanoma: pattern of sun exposure and histological subtypes.
    Br J Dermatol. 2015;172:560-1.
    PubMed     Text format    


  39. SWETTER SM
    Thinner melanomas and improved survival among men in Sweden from 1997 to 2011.
    Br J Dermatol. 2015;172:559-60.
    PubMed     Text format    


  40. MCGREGOR JM, Sasieni P
    Sentinel node biopsy in cutaneous melanoma: time for consensus to better inform patient choice.
    Br J Dermatol. 2015;172:552-4.
    PubMed     Text format    


    February 2015
  41. CARRERA C
    High-risk melanoma patients: can unnecessary naevi biopsies be avoided?
    Br J Dermatol. 2015;172:313-5.
    PubMed     Text format    


    January 2015
  42. KASSIANOS AP, Emery JD, Murchie P, Walter FM, et al
    Smartphone applications for melanoma detection by community, patient and generalist clinician users: a review.
    Br J Dermatol. 2015 Jan 20. doi: 10.1111/bjd.13665.
    PubMed     Text format     Abstract available


  43. JEUDY G, Dalac-Rat S, Bonniaud B, Hervieu A, et al
    Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
    Br J Dermatol. 2015;172:1454-5.
    PubMed     Text format    


    December 2014
  44. LIVINGSTONE E, Eigentler TK, Windemuth-Kieselbach C, Hauschild A, et al
    Actual practice of melanoma follow-up and treatment in Germany: Results of a prospective, longitudinal cohort study.
    Br J Dermatol. 2014 Dec 15. doi: 10.1111/bjd.13612.
    PubMed     Text format     Abstract available


  45. MORTON RL
    Essential inputs for studies of cost-effectiveness analysis in melanoma.
    Br J Dermatol. 2014;171:1294-5.
    PubMed     Text format    


  46. NALDI L
    Melanoma excision: how deep must we go?
    Br J Dermatol. 2014;171:1291-2.
    PubMed     Text format    


  47. BERMUDEZ Y
    Ultraviolet involvement in melanocyte transformation to melanoma.
    Br J Dermatol. 2014;171:1289.
    PubMed     Text format    


    November 2014
  48. GONZALEZ-ALVAREZ T, Carrera C, Bennassar A, Vilalta A, et al
    Dermoscopy structures predictors of sentinel lymph node positivity in cutaneous melanoma.
    Br J Dermatol. 2014 Nov 21. doi: 10.1111/bjd.13552.
    PubMed     Text format     Abstract available


  49. HUNGER RE, Seyed Jafari SM, Angermeier S, Shafighi M, et al
    Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome.
    Br J Dermatol. 2014 Nov 13. doi: 10.1111/bjd.13478.
    PubMed     Text format     Abstract available


  50. LONGO C, Piana S, Marghoob A, Cavicchini S, et al
    Morphologic features of nevoid melanoma Results of a Multicenter Study of the International Dermoscopy Society.
    Br J Dermatol. 2014 Nov 12. doi: 10.1111/bjd.13524.
    PubMed     Text format     Abstract available


  51. GARCIA-CASADO Z, Traves V, Banuls J, Niveiro M, et al
    BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    Br J Dermatol. 2014 Nov 10. doi: 10.1111/bjd.13521.
    PubMed     Text format     Abstract available


  52. KITTLER H
    B-RAF, naevi and melanoma: a complex relationship.
    Br J Dermatol. 2014;171:931-932.
    PubMed     Text format    


    October 2014
  53. JIANG AJ, Rambhatla PV, Eide MJ
    A Systematic Review of Socioeconomic and Lifestyle Factors and Melanoma.
    Br J Dermatol. 2014 Oct 30. doi: 10.1111/bjd.13500.
    PubMed     Text format     Abstract available


  54. DABOUZ F, Barbe C, Lesage C, Le Clainche A, et al
    Clinical and histological features of head and neck melanoma: a population-based study in France.
    Br J Dermatol. 2014 Oct 21. doi: 10.1111/bjd.13489.
    PubMed     Text format     Abstract available


  55. MENIS D, Maronas-Jimenez L, Rodriguez-Peralto J, Martin-Llamas R, et al
    Two Spanish cases of Atypical Melanosis of the Foot, an early stage of Acral Lentiginous Melanoma in situ.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13485.
    PubMed     Text format     Abstract available


  56. PONTI G, Manfredini M, Tomasi A, Pellacani G, et al
    Distinctive clinical and dermoscopic features of BRAFp.V600K mutated melanomas.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13484.
    PubMed     Text format     Abstract available


  57. LYTH J, Eriksson H, Hansson J, Ingvar C, et al
    Trends in cutaneous malignant melanoma in Sweden 1997-2011: Thinner tumours and improved survival among men.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13483.
    PubMed     Text format     Abstract available


  58. EVANS CL
    Peering under the skin: measuring melanoma depth with ultrasound and optical coherence tomography.
    Br J Dermatol. 2014;171:690-1.
    PubMed     Text format    


    September 2014
  59. WATTS CG, Dieng M, Morton RL, Mann GJ, et al
    Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review.
    Br J Dermatol. 2014 Sep 10. doi: 10.1111/bjd.13403.
    PubMed     Text format     Abstract available


    August 2014
  60. STANGANELLI I, Longo C, Mazzoni L, Magi S, et al
    Integration of reflectance confocal microscopy in sequential dermoscopy follow-up improves melanoma detection accuracy.
    Br J Dermatol. 2014 Aug 25. doi: 10.1111/bjd.13373.
    PubMed     Text format     Abstract available


  61. MOSCARELLA E, Al Jalbout S, Piana S, Argenziano G, et al
    The stars within the melanocytic garden: Unusual variants of Spitz nevi.
    Br J Dermatol. 2014 Aug 13. doi: 10.1111/bjd.13347.
    PubMed     Text format     Abstract available


  62. LAWRENCE CM, Rahim R, Charlton F, Husain A, et al
    Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results.
    Br J Dermatol. 2014;171:298-303.
    PubMed     Text format     Abstract available


    July 2014
  63. BERETTI F, Manni P, Longo C, Argenziano G, et al
    CD271 is expressed in melanoma with more aggressive behavior with correlation of characteristic morphology in in vivo reflectance confocal microscopy.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13301.
    PubMed     Text format     Abstract available


  64. BRUGIERE C, Stefan A, Morice C, Cornet E, et al
    Vemurafenib skin phototoxicity is indirectly linked to UVA-MED decrease.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13300.
    PubMed     Text format     Abstract available


  65. TROMME I, Devleesschauwer B, Beutels P, Richez P, et al
    Health related quality of life in melanoma patients expressed as utilities and disability weights.
    Br J Dermatol. 2014 Jul 12. doi: 10.1111/bjd.13262.
    PubMed     Text format     Abstract available


  66. ANFORTH R, Carlos G, Clements A, Kefford R, et al
    Cutaneous Adverse Events in Patients Treated with BRAF Inhibitor Based Therapies for Metastatic Melanoma for Longer than 52 Weeks.
    Br J Dermatol. 2014 Jul 9. doi: 10.1111/bjd.13200.
    PubMed     Text format     Abstract available


    June 2014
  67. SELLA T, Goren I, Shalev V, Shapira H, et al
    Incidence Trends of Keratinocytic Skin Cancers and Melanoma in Israel 2006-2011.
    Br J Dermatol. 2014 Jun 28. doi: 10.1111/bjd.13213.
    PubMed     Text format     Abstract available


  68. GAMBICHLER T, Kempka J, Kampilafkos P, Bechara FG, et al
    Clinicopathological characteristics of 270 lentigo maligna and lentigo maligna melanoma patients: data of a German Skin Cancer Center.
    Br J Dermatol. 2014 Jun 24. doi: 10.1111/bjd.13204.
    PubMed     Text format     Abstract available


  69. DE TROYA-MARTIN M, Rivas-Ruiz F, Blazquez-Sanchez N, Fernandez-Canedo I, et al
    Spanish version of the "skin cancer index". A questionnaire for measuring quality of life in patients with cervicofacial non-melanoma skin cancer.
    Br J Dermatol. 2014 Jun 7. doi: 10.1111/bjd.13173.
    PubMed     Text format     Abstract available


  70. ERIKSSON H, Frohm-Nilsson M, Jaras J, Kanter-Lewensohn L, et al
    Prognostic factors in localized invasive primary cutaneous malignant melanoma -results of a large population-based study.
    Br J Dermatol. 2014 Jun 7. doi: 10.1111/bjd.13171.
    PubMed     Text format     Abstract available


    May 2014
  71. PELLACANI G, Pepe P, Casari A, Longo C, et al
    Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study.
    Br J Dermatol. 2014 May 29. doi: 10.1111/bjd.13148.
    PubMed     Text format     Abstract available


  72. MEYER N, Lauwers-Cances V, Lourari S, Laurent J, et al
    High frequency ultrasonography but not 930nm-optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study.
    Br J Dermatol. 2014 May 23. doi: 10.1111/bjd.13129.
    PubMed     Text format     Abstract available


  73. MALVEHY J, Hauschild A, Curiel-Lewandrowski C, Mohr P, et al
    Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multi-centre, prospective and blinded clinical trial on efficacy and safety.
    Br J Dermatol. 2014 May 19. doi: 10.1111/bjd.13121.
    PubMed     Text format     Abstract available


  74. CHEVOLET I, Speeckaert R, Haspeslagh M, Neyns B, et al
    Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
    Br J Dermatol. 2014 May 10. doi: 10.1111/bjd.13100.
    PubMed     Text format     Abstract available


    April 2014
  75. POZZOBON FC, Puig-Butille JA, Gonzalez-Alvarez T, Carrera C, et al
    Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Br J Dermatol. 2014 Apr 21. doi: 10.1111/bjd.13069.
    PubMed     Text format     Abstract available


  76. TALAGANIS JA, Biello K, Plaka M, Polydorou D, et al
    Demographic, behavioural and physician-related determinants of early melanoma detection in a low incidence population.
    Br J Dermatol. 2014 Apr 21. doi: 10.1111/bjd.13068.
    PubMed     Text format     Abstract available


  77. CHEVALIER V, Barbe C, Le Clainche A, Arnoult G, et al
    Comparison of Anatomic Locations of Cutaneous Melanoma in Men and Women: A Population-Based Study in France.
    Br J Dermatol. 2014 Apr 11. doi: 10.1111/bjd.13052.
    PubMed     Text format     Abstract available


  78. KOSE K, Cordova M, Duffy M, Flores ES, et al
    Video-Mosaicing of Reflectance Confocal Images For Examination of Extended Areas of Skin In Vivo.
    Br J Dermatol. 2014 Apr 10. doi: 10.1111/bjd.13050.
    PubMed     Text format     Abstract available


  79. HOLLESTEIN LM, Nijsten T
    The association between beta-blockers and melanoma survival: evidence of absence or absence of evidence?
    Br J Dermatol. 2014;170:764-5.
    PubMed     Text format    


    March 2014
  80. ROTA M, Negri E, Pelucchi C, La Vecchia C, et al
    Does alcohol consumption increase risk of cutaneous melanoma? Comments on a recent meta-analysis: reply from authors.
    Br J Dermatol. 2014 Mar 26. doi: 10.1111/bjd.12996.
    PubMed     Text format     Abstract available


  81. SUN V, Zhou WB, Majid S, Kashani-Sabet M, et al
    MicroRNA-mediated regulation of melanoma.
    Br J Dermatol. 2014 Mar 26. doi: 10.1111/bjd.12989.
    PubMed     Text format     Abstract available


  82. PASTUSHENKO I, Vermeulen PB, Van den Eynden GG, Rutten A, et al
    Mechanisms of tumour vascularisation in cutaneous malignant melanoma: clinical implications.
    Br J Dermatol. 2014 Mar 18. doi: 10.1111/bjd.12973.
    PubMed     Text format     Abstract available


  83. CHEN GC, Zhang Y
    Does alcohol consumption increase risk of cutaneous melanoma? Comments on a recent meta-analysis.
    Br J Dermatol. 2014 Mar 18. doi: 10.1111/bjd.12971.
    PubMed     Text format     Abstract available


  84. PICARD M, Pham Dang N, D'Incan M, Mansard S, et al
    Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
    Br J Dermatol. 2014 Mar 6. doi: 10.1111/bjd.12939.
    PubMed     Text format     Abstract available


  85. DE WAAL AC, van Harten-Gerritsen AS, Aben KK, Kiemeney LA, et al
    Impact of mitotic activity on the pathological sub-staging of pT1 cutaneous melanoma.
    Br J Dermatol. 2014 Mar 5. doi: 10.1111/bjd.12898.
    PubMed     Text format     Abstract available


  86. MCCOURT C, Coleman HG, Murray LJ, Cantwell MM, et al
    Beta-blocker usage after malignant melanoma diagnosis and survival: A population-based nested case-control study.
    Br J Dermatol. 2014 Mar 5. doi: 10.1111/bjd.12894.
    PubMed     Text format     Abstract available


  87. FORSEA AM, Del Marmol V, Stratigos A, Geller AC, et al
    Melanoma Prognosis in Europe: Far from Equal.
    Br J Dermatol. 2014 Mar 3. doi: 10.1111/bjd.12923.
    PubMed     Text format     Abstract available


    February 2014
  88. ROTA M, Pasquali E, Bellocco R, Bagnardi V, et al
    Alcohol drinking and cutaneous melanoma risk - A systematic review and dose-risk meta-analysis.
    Br J Dermatol. 2014 Feb 3. doi: 10.1111/bjd.12856.
    PubMed     Text format     Abstract available


  89. SACHSE MM, Wagner G
    Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
    Br J Dermatol. 2014;170:475-7.
    PubMed     Text format    


    January 2014
  90. ECHEVERRIA B, Bulliard JL, Guillen C, Nagore E, et al
    Indicators for the total number of melanocytic naevi: an adjunct for screening campaigns. Observational study on 292 patients.
    Br J Dermatol. 2014;170:144-9.
    PubMed     Text format     Abstract available


  91. RIVERS JK
    Skin cancer: more than skin deep?
    Br J Dermatol. 2014;170:8.
    PubMed     Text format    


  92. FOGARTY GB, Hong A, Scolyer RA, Lin E, et al
    Radiotherapy for lentigo maligna: a literature review and recommendations for treatment.
    Br J Dermatol. 2014;170:52-8.
    PubMed     Text format     Abstract available


    August 2013
  93. DIFFEY B
    Sunbeds and young people: an easy target for legislation?
    Br J Dermatol. 2013;169:236-7.
    PubMed     Text format    


    July 2013
  94. ANFORTH R , Blumetti TC, Clements A, Kefford R, et al
    Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors.
    Br J Dermatol. 2013 Jul 20. doi: 10.1111/bjd.12519.
    PubMed     Text format     Abstract available


    June 2013
  95. BLACK N
    Patient-reported outcome measures in skin cancer.
    Br J Dermatol. 2013;168:1151.
    PubMed     Text format    


  96. DE VRIES K, Rellum R, Habets JM, Prens EP, et al
    A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod.
    Br J Dermatol. 2013;168:1362-4.
    PubMed     Text format    


    March 2013
  97. GIBBONS E , Casanas I Comabella C, Fitzpatrick R
    A structured review of patient-reported outcome measures for patients with skin cancer, 2013.
    Br J Dermatol. 2013 Mar 14. doi: 10.1111/bjd.12310.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Pfizer Oncology.

Design: